The scientific journal Science has selected Cancer Immunotherapy as breakthrough therapy of the year 2013.
Patients with metastatic Melanoma will be familiar with the drugs- like Ipilimumab, Nivolumab and other CTL4, PD1 and PDL1 antibodies- that make use of the body's own immune system to attack the cancer and that for the first time are able to provide long-term survival in Melanoma.
Read the full article under: http://www.sciencemag.org/content/342/6165/1432.full
No comments:
Post a Comment